Eledon Pharmaceuticals Inc. (ELDN) carries a Roarable Rating of D (Sell) with 49/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-01, Eledon Pharmaceuticals Inc. (NASDAQ: ELDN) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 49/100 at a spot price of $3.04 (+10.15% 1D, market cap $247.0M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 14/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, ELDN ranks #362 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ELDN carries a Roarable D (49/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, EVMN (Evommune Inc.) holds a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $247.1M) and LFCR (Lifecore Biomedical Inc.) posts a D grade (51/100 RQD, P/E N/A, ROIC —, cap $246.8M). Among the 5-stock peer group, ELDN leads on earnings multiple (N/A) while ELDN leads on capital efficiency (-35.0% ROIC).
Per ELDN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001404281), Eledon Pharmaceuticals Inc. generated $0 in revenue, -$45.6M in net income, and -$62.3M in free cash flow against $169.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
FRED Regime × Technicals: 52% of 52W Range • RSI-14 at 58 (BULLISH MOMENTUM)
20D Institutional Volume Accumulation (±12.5% realized swing band)
Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
While ELDN currently carries a cautious 49/100 (D) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.68) and Max Pain ($3.19) forces dealer call-delta covering toward $4.83.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Eledon Pharmaceuticals Inc. (ELDN) surged +10.15% to $3.04, trading at 52% of its 52-week range ($1.35 – $4.6). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Tegoprubart-treated patients demonstrated a mean improvement on the total MTSOSD-59R symptom occurrence scale at 12 months while tacrolimus-treated patients experienced a mean worsening of symptom occurrence Statisticall
Tegoprubart-treated patients demonstrated a mean improvement on the total MTSOSD-59R symptom occurrence scale at 12 months while tacrolimus-treated patients experienced a mean worsening of symptom
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on ELDN today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for ELDN. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Eledon Pharmaceuticals Inc. (ELDN) ranks #362 by composite RQD confidence (49/100, grade D) and #549 by equity capitalization ($247.0M). Within this direct 5-issuer industry benchmark cohort, ELDN leads on earnings valuation at N/A trailing P/E, while ELDN leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. LFCR currently holds the highest overall quantitative score in the immediate peer group at 51/100 (D) compared with ELDN at 49/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ELDN
ACTIVE
Eledon Pharmaceuticals Inc. | D | 49/100 | — | — | -35.0% | +10.15% | $247.0M | Benchmark Subject |
| EVMN Evommune Inc. | D- | 43/100 | — | — | -35.0% | +7.92% | $247.1M | /evmn-vs-eldn → |
| LFCR Lifecore Biomedical Inc. | D | 51/100 | — | — | — | +0.15% | $246.8M | /lfcr-vs-eldn → |
| VNDA Vanda Pharmaceuticals Inc. | D- | 37/100 | — | — | -35.0% | +1.25% | $244.9M | /vnda-vs-eldn → |
| CAMP CAMP4 Therapeutics Corporation | E | 34/100 | — | — | -35.0% | +6.85% | $244.7M | /camp-vs-eldn → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Eledon Pharmaceuticals Inc. (ELDN) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$45.6M, operating cash flow of -$62.3M, and free cash flow of -$62.3M (-31.9% YoY). On the balance sheet, ELDN closed FY2025 with $169.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$45.6M | -$62.3M | -$62.3M | $169.0M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$36.2M | -$47.3M | -$47.3M | $177.4M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$116.5M | -$39.5M | -$39.5M | — | — |
As of 2026-11-01, Eledon Pharmaceuticals Inc. (NASDAQ: ELDN) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 49/100 at a spot price of $3.04 (+10.15% 1D, market cap $247.0M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 14/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, ELDN ranks #362 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ELDN carries a Roarable D (49/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, EVMN (Evommune Inc.) holds a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $247.1M) and LFCR (Lifecore Biomedical Inc.) posts a D grade (51/100 RQD, P/E N/A, ROIC —, cap $246.8M). Among the 5-stock peer group, ELDN leads on earnings multiple (N/A) while ELDN leads on capital efficiency (-35.0% ROIC).
Per ELDN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001404281), Eledon Pharmaceuticals Inc. generated $0 in revenue, -$45.6M in net income, and -$62.3M in free cash flow against $169.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
ELDN last traded at $3.04 (+10.15% on volume of 3,109,182 shares), positioning the stock +13.43% above its 50-day simple moving average ($2.68) and -2.25% below its 200-day simple moving average ($3.11). Across its 52-week range of $1.35 to $4.60, ELDN sits at the 52.0% percentile with a 14-day RSI of 58.0 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($2.66 to $3.42).
Why ELDN Stock surged +10.15% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Paper Trading Arena account.